KSBB Journal

The Korean Society for Biotechnology and Bioengineering (한국생물공학회)
권호 표지

Development of Probiotic Products and Challenges

프로바이오틱 제품 개발 동향과 과제

  • Received : 2010.07.25
  • Accepted : 2010.08.24
  • Published : 2010.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Probiotics beneficially affect the health of the host via various mechanisms in the intestine. Recent developments in probiotic products have mainly been made to maximize probiotic effects in human. In this regard, probiotic products containing doubly coated or encapsulated cells, multi-species probiotics, or high viable cell number (1010 viable cells/gram or more) have been developed and are already available in the market. Until now, the majority of probiotics contain live cells but little attention has been paid to other alternative products such as heat-killed cell or bacteriocin-containing ones, which could have broad applications due to advantages over live cell-based probiotics, such as safety and stability. In addition, genetically engineered lactic acid bacteria could be of great importance in the field of alimentary health if they are carefully designed for biological safety. Although a number of probiotics are marketed by claiming health benefits, regulations for health claims will be more stringent. Therefore sufficient scientific and clinical evidences supporting the safety and efficacy of the potential probiotic strain will be required by the regulatory authority for a health claim, which thus may have a huge impact on the future probiotic market.

프로바이오틱스는 위장관에서 고유의 생리활성을 발휘하기 때문에 섭취 후 최대한 장까지 사멸하지 않고 도달하도록 하는 코팅이나 encapsulation 기술이 개발되어 왔다. 이와 함께 제품의 형태도 여러 종류의 유산균이 포함된 multispecies probiotics가 선호되는 추세이며 높은 생균수를 가지는 제품들이 개발되고 있다. 프로바이오토틱 시장은 현재까지 생균 중심의 제품들이 대부분을 차지하고 있으나 사균체 제품 또는 박테리오신과 같은 항균물질을 포함하는 제품 또한 다양한 분야에 적용될 수 있고 생균제와 비교하여 여러가지 장점을 가지고 있어 관련 제품개발이 이루어져야 할 것으로 보인다. 프로바이오틱 제품들은 살아 있는 생균제로서 질환특이적 효능을 바탕으로 개발되고 있으나 질환개선 효능 표시에 대한 규제가 강화되고 있어 이에 대한 대비가 필요하다. 이를 위해 제품에 사용된 strain의 동정, 안전성 및 기능성에 대한 과학적 증거가 제시되어야 할 것이며 임상을 통한 안전성과 효능에 대한 검증 자료가 필요할 것으로 보인다. 이와 같은 프로바이오틱스 제품의 헬스클레임에 대한 엄격해진 검증은 앞으로 프로바이오틱 시장에 큰 영향을 미칠 것으로 판단된다.

Keywords

References

  1. Kassinen, A., L. Krogius-Kurikka, H. Makivuokko, T. Rinttilä, L. Paulin, J. Corander, E. Malinen, J. Apajalahti, and A. Palva (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133: 24-33. https://doi.org/10.1053/j.gastro.2007.04.005
  2. Young, V. B. and T. M. Schmidt (2004) Antibioticassociated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J. Clin Microbiol. 42: 1203-1206. https://doi.org/10.1128/JCM.42.3.1203-1206.2004
  3. Swidsinski, A., A. Ladhoff, Pernthaler, S. Swidsinski, V. Loening-Baucke, M. Ortner, J. Weber, U. Hoffmann, S. Schreiber, M. Dietel, and H. Lochs (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122: 44-54. https://doi.org/10.1053/gast.2002.30294
  4. Fasoli, S., M. Marzotto, L. Rizzotti, F. Rossi, F. Dellaglio, and S. Torriani (2003) Bacterial composition of commercial probiotic products as evaluated by PCRDGGE analysis. Int. J. Food Microbiol. 82: 59-70. https://doi.org/10.1016/S0168-1605(02)00259-3
  5. Hamilton-Miller, J. M., S. Shah, and J. T. Winkler (1999) Public health issues arising from microbiological and labelling quality of foods and supplements containing probiotic microorganisms. Public Health Nutr. 2: 223-229.
  6. Temmerman, R., I. Scheirlinck, G. Huys, and J. Swings (2003) Culture in dependent analysis of probiotic products by denaturing gradient gel electrophoresis. Appl. Environ. Microbiol. 69: 220-226. https://doi.org/10.1128/AEM.69.1.220-226.2003
  7. Dunne, C., L. Murphy, S. Flynn, L. O'Mahony, S. O'Halloran, M. Feeney, D. Morrissey, G. Thornton, G. Fitzgerald, C. Daly, B. Kiely, E. M. Quigley, G. C. O'Sullivan, F. Shanahan, and J. K. Collins (1999) Probiotics: from myth to reality. demonstration of functionality in animal models of disease and in human clinical trials. Anton. Leeuw. 76: 279-292. https://doi.org/10.1023/A:1002065931997
  8. Rolfe, R. D. (2000) The role of probiotic cultures in the control of gastrointestinal health. J. Nutr. 130: 396S-402S. https://doi.org/10.1093/jn/130.2.396S
  9. Fuller, R. (1989) Probiotics in man and animal. J. Appl. Bacteriol. 66: 365-378. https://doi.org/10.1111/j.1365-2672.1989.tb05105.x
  10. Lee, Y. K., K. Nomoto, S. Salminen, and S. L. Gorbach. (1999) Handbook of Probiotics. John Wiley & Sons, New York.
  11. Salminen, S., A. Ouwehand, Y. Benno, and Y. K. Lee (1999) Probiotics: how should they be defined? Trends Food Sci. Technol. 10: 107-110. https://doi.org/10.1016/S0924-2244(99)00027-8
  12. Li, N., W. M. Russell, M. Douglas-escobar, N. Hauser, M. Lopez, and J. Neu (2009) Live and heat-killed Lactobacillus rhamnosus GG: effects on proinflammatory and anti-inflammatory cytokines/chemokines in gastrostomyfed infant rats. Pediatr. Res. 66: 203-207. https://doi.org/10.1203/PDR.0b013e3181aabd4f
  13. Hirose, Y., S. Murosaki, Y. Yamamoto, K. Muroyama, Y. Miwa, A. Fujishima, and B. Lynch (2009) Safety studies of LP20 powder produced from heat-killed Lactobacillus plantarum L-137. Regul. Toxicol. Pharmacol. 54: 214-220. https://doi.org/10.1016/j.yrtph.2009.03.007
  14. Kabak, B. and I. Var (2008) Factors affecting the removal of aflatoxin M1 from food model by Lactobacillus and Bifidobacterium strains. J. Environ. Sci. Health B. 43: 617-624. https://doi.org/10.1080/03601230802234740
  15. Kim, D. and M. J. Chung (2004) A probiotics condensate mixture: Novel antimicrobial application. Nutrafoods 3: 11-16.
  16. Kang, B. S., J. G. Seo, G. S. Lee, J. H. Kim, S. Y. Kim, Y. W. Han, H. Kang, H. O. Kim, J. H. Rhee, M. J. Chung, and Y. M. Park (2009) Antimicrobial activity of enterocins from Enterococcus faecalis SL-5 against Propionibacterium acnes, the causative agent in acne vulgaris, and its therapeutic effect. J. Microbiol. 47: 101-109. https://doi.org/10.1007/s12275-008-0179-y
  17. Hillman, J. D. (2002) Genetically modified Streptococcus mutans for the prevention of dental caries. Anton. Leeuw. 82: 361-366. https://doi.org/10.1023/A:1020695902160
  18. Kruger, C., Y. Hu, Q. Pan, H. Marcotte, A. Hultberg, D. Delwar, P. J. van Dalen, P. H. Pouwels, R. J. Leer, C. G. Kelly, C. van Dollenweerd, J. K. Ma, and L. Hammarström (2002) In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nat. Biotechnol. 20: 702-706. https://doi.org/10.1038/nbt0702-702
  19. Drouault, S., C. Juste, P. Marteau, P. Renault, and G. Corthier (2002) Oral treatment with Lactococcus lactis expressing Staphylococcus hyicus lipase enhances lipid digestion in pigs with induced pancreatic insufficiency. Appl. Environ. Microbiol. 68: 3166-3168. https://doi.org/10.1128/AEM.68.6.3166-3168.2002
  20. Lee, Y. K. (2009) Probiotic microorganisms. pp. 3-176. In: Y. K. Lee and S. Salminen (eds.). Handbook of probiotics and prebiotics. John Wiley & Son, Inc., New Jersey, USA.
  21. Huys, G., M. Vancanneyt, K. D'Haene, V. Vankerckhoven, H. Goossens, and J. Swings (2006) Accuracy of species identity of commercial bacterial cultures intended for probiotic or nutritional use. Res. Microbiol. 157: 803-810. https://doi.org/10.1016/j.resmic.2006.06.006
  22. Hamilton-Miller, J. M. and S. Shah (2002) Deficiencies in microbiological quality and labelling of probiotic supplements. Int. J. Food Microbiol. 72: 175-176. https://doi.org/10.1016/S0168-1605(01)00703-6
  23. The European Union, Regulations (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health claims made on foods. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:32006R1924R(01):EN:NOT.(2010).
  24. EFSA panel on Dietetic Products, Nutrition and Allergies (2009) Scientific opinion on the substantiation of health claims related to non-characterised microorganisms pursuant to Article 13(1) of regulation (EC) N0 1924/ 2006. EFSA Journal 7: 1247. https://doi.org/10.2903/j.efsa.2009.1247
  25. EFSA panel on Dietetic Products, Nutrition and Allergies (2010) Scientific Opinion on the substantiation of health claims related to Bifidobacterium animalis Lafti B94 (CBS118.529) and decreasing potentially pathogenic intestinal microorganisms (ID 867) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 7: 1232.
  26. EFSA panel on Dietetic Products, Nutrition and Allergies (2009) Scientific Opinion on the substantiation of health claims related to Lactobacillus plantarum 299v (DSM 9843) and decreasing potentially pathogenic intestinal microorganisms (ID 1084) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 7: 1242. https://doi.org/10.2903/j.efsa.2009.1242
  27. EFSA panel on Dietetic Products, Nutrition and Allergies (2010) Scientific Opinion on the substantiation of health claims related to Lactobacillus plantarum 299v (DSM 9843) and "immune system" (ID 1081), pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 8: 1488. https://doi.org/10.2903/j.efsa.2010.1488